COCP - Cocrystal Pharma Inc logo

Cocrystal Pharma Inc

COCP

Cocrystal Pharma develops antiviral therapeutics targeting influenza, coronaviruses, norovirus, and hepatitis C using structure-based technologies. Its clinical-stage pipeline includes drugs for pandemic and seasonal flu, norovirus, and HCV infections.

โš•๏ธ Healthcare NASDAQ Listed 2011 $ USD
$1,000 invested 10 years ago โ†’$5today

Score Overview

1 Year
Scoreโ€”
Net Growth-12.54%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.2
Net Growth29.94%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-93.92%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth86.73%
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-82.10%
Net Trend46%
Net Income Consistency
Rev Growth-97.38%
Rev Trend27%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cocrystal Pharma Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. COCP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.95โ€”
1 Year2025-10-23
$ 1.06-10.38%
5 Years2021-10-22
$ 11.52-91.75%
10 Years2016-10-21
$ 176.40-99.46%
All Time2011-05-19
$ 5.50-82.73%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 330K-$ 9M$ 2M
2025$ 0.00-$ 8M$ 7M
2024$ 0.00-$ 17M$ 9M
2023$ 0.00-$ 17M$ 26M
2022$ 0.00-$ 38M$ 37M
2021$ 5M-$ 14M$ 58M
2020$ 2M-$ 9M$ 33M
2019$ 6M-$ 48M$ 7M
2018$ 0.00-$ 49M$ 2M
2017$ 0.00-$ 613K$ 748K
2016$ 0.00-$ 74M$ 3M
2015$ 78K-$ 50M$ 9M
2014$ 5M
2013-$ 19M$ 589.47K
2012-$ 7M$ 62.3K
IPO2011$ 12M-$ 5M$ 416.33K
COCP - Cocrystal Pharma Inc logo

Cocrystal Pharma Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 2M to $ 0.00 and net income went from -$ 9M to -$ 8M. Revenue increased in 1 of those 5 years; net income in 3.

Across Cocrystal Pharma Inc's full reported history, from 2011 to 2025, revenue declined from $ 12M to $ 0.00 and net income went from -$ 5M to -$ 8M. Revenue increased in 27% of the years measured; net income in 46%.

Cocrystal Pharma Inc currently holds a 5-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Membership

Explore COCP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies